Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01460134 · ClinicalTrials.gov registry record · Phase 1
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1 study, sponsored by Celldex Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT01460134 is a Phase 1 study that has completed, run by Celldex Therapeutics. The registered enrollment target is 90 participants.
The verdict
NCT01460134, a Phase 1 study, has completed, sponsored by Celldex Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
This is a study of CDX-1127, a therapy that targets the immune system and may act to promote anti-cancer effects. The study enrolls patients with hematologic cancers (certain leukemias and lymphomas), as well as patients with select types of solid tumors.
Interventions
- DRUG CDX-1127
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2011-10 |
| Est. Completion | 2017-10-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01460134
The ClinicalTrials.gov registry entry for NCT01460134 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CDX-1127 is the first listed.
NCT01460134 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01460134 about?
NCT01460134 is a clinical study titled "A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers". This is a study of CDX-1127, a therapy that targets the immune system and may act to promote anti-cancer effects. The study enrolls patients with hematologic cancers (certain leukemias and lymphomas), as well as patients with select types of solid tumors.
What is the current status of trial NCT01460134?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2011-10. Estimated completion is 2017-10-16.
What interventions are being tested in trial NCT01460134?
The interventions under investigation include: CDX-1127 (DRUG).
Who is sponsoring clinical trial NCT01460134?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.